Loading...
XSHE002940
Market cap365mUSD
Jan 08, Last price  
13.40CNY
1D
0.30%
1Q
-7.71%
IPO
-22.90%
Name

Zhejiang Anglikang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002940 chart
P/E
19.34
P/S
1.65
EPS
0.69
Div Yield, %
0.00%
Shrs. gr., 5y
6.07%
Rev. gr., 5y
5.31%
Revenues
1.63b
+3.66%
681,508,471773,793,586671,580,994873,154,4131,255,047,6581,396,193,9061,289,647,1011,380,377,6361,568,437,2191,625,866,701
Net income
138m
+8.70%
50,127,70064,027,33482,187,653101,085,352108,697,464112,269,989163,719,116119,844,202127,296,292138,372,383
CFO
277m
+49.89%
50,458,000138,588,381141,744,622193,773,170133,612,108213,493,104198,612,986197,652,364184,746,829276,909,170
Dividend
Jun 17, 20240.21 CNY/sh
Earnings
May 15, 2025

Profile

Zhejiang Anglikang Pharmaceutical Co., Ltd. engages in the production and sale of pharmaceutical materials, pharmaceutic preparations, and medical empty capsules. The company offers products in anti-infection, antihypertensive, digestive system, and respiratory preparation. It is also involved in research and development of drugs for featuring oral cephalosporins, cardiovascular, kidney, and central nervous diseases. The company was founded in 2001 and is based in Shengzhou, China.
URL
http://www.alkpharm.com/
IPO date
Oct 23, 2018
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,625,867
3.66%
1,568,437
13.62%
Cost of revenue
1,394,861
1,359,542
Unusual Expense (Income)
NOPBT
231,006
208,895
NOPBT Margin
14.21%
13.32%
Operating Taxes
24,135
14,957
Tax Rate
10.45%
7.16%
NOPAT
206,871
193,937
Net income
138,372
8.70%
127,296
6.22%
Dividends
(28,166)
Dividend yield
0.76%
Proceeds from repurchase of equity
(20,120)
63,324
BB yield
0.46%
-1.71%
Debt
Debt current
133,143
195,202
Long-term debt
423,950
150,000
Deferred revenue
17,847
9,733
Other long-term liabilities
Net debt
(604,058)
(692,413)
Cash flow
Cash from operating activities
276,909
184,747
CAPEX
(124,946)
Cash from investing activities
(178,498)
Cash from financing activities
21,227
376,616
FCF
(17,057)
299,361
Balance
Cash
869,746
804,764
Long term investments
291,406
232,852
Excess cash
1,079,858
959,194
Stockholders' equity
1,053,732
894,117
Invested Capital
1,353,477
1,071,452
ROIC
17.06%
20.57%
ROCE
9.54%
10.62%
EV
Common stock shares outstanding
200,540
198,473
Price
21.71
16.33%
18.66
8.00%
Market cap
4,353,717
17.54%
3,703,911
8.59%
EV
3,995,725
3,154,993
EBITDA
311,492
269,999
EV/EBITDA
12.83
11.69
Interest
14,719
6,395
Interest/NOPBT
6.37%
3.06%